MedWatch

Eli Lilly has to wait a while longer for FDA verdict

Partners Eli Lilly and Incyte will have to wait until Q3 to find out whether the US health authorities can approve their drug Oluminant as a treatment for atopic dermatitis.

Photo: MIKE SEGAR/REUTERS / X90033

The US Food and Drug Administration (FDA) has extended the review period for Eli Lilly's application to get approval for the drug Olumiant, which treats atopic dermatitis in adults, according to an Eli Lilly press announcement.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs